Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Inactivating or Inferred Inactivating NF1 Alterations: A ComboMATCH Treatment Trial
(See required screening study ECOG-ACRIN EAY191)
